Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of "Hold" from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been given an average rating of "Hold" by the sixteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $171.85.

A number of research firms have recently weighed in on CRL. Barclays raised their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a research note on Thursday, May 8th. Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their target price for the company from $188.00 to $182.00 in a research report on Friday, May 23rd.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president owned 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Securities LLC boosted its holdings in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after buying an additional 81 shares in the last quarter. Wahed Invest LLC lifted its position in Charles River Laboratories International by 6.5% in the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after acquiring an additional 81 shares during the last quarter. Brooklyn Investment Group boosted its stake in Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after acquiring an additional 86 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Charles River Laboratories International by 16.3% during the fourth quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company's stock worth $118,000 after purchasing an additional 90 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its position in shares of Charles River Laboratories International by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 15,694 shares of the medical research company's stock worth $2,897,000 after purchasing an additional 102 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Trading Down 0.2%

Shares of CRL stock opened at $157.12 on Monday. Charles River Laboratories International has a twelve month low of $91.86 and a twelve month high of $254.15. The stock has a market cap of $7.72 billion, a price-to-earnings ratio of -241.72, a PEG ratio of 5.32 and a beta of 1.49. The company's 50-day moving average price is $140.70 and its 200-day moving average price is $152.30. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.27 EPS. As a group, equities analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.